Shares of Structure Therapeutics Inc. (NASDAQ: GPCR) surged today, reaching a 52-week high as investor optimism grows. The stock's recent performance reflects a bullish sentiment following BMO Capital's endorsement, which maintains an 'Outperform' rating and sets a $100 price target, largely driven by expectations surrounding the upcoming Phase 2b obesity trial results.
Despite reporting a widened net loss of $65.7 million in Q3 2025, the company boasts a robust cash position of $799 million, positioning it well to continue its research and development efforts in the competitive biotech landscape. Analysts note that while GPCR presents significant investment potential, the market remains crowded, with certain AI stocks also being highlighted for their upside potential and lower risk profiles.
As Structure Therapeutics advances its pipeline of oral small-molecule treatments for metabolic diseases, the completion of its obesity studies by year-end could further influence market sentiment and investor interest.
Wall Street analysts forecast GPCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GPCR is 104.00 USD with a low forecast of 65.00 USD and a high forecast of 130.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
Wall Street analysts forecast GPCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GPCR is 104.00 USD with a low forecast of 65.00 USD and a high forecast of 130.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 89.050
Low
65.00
Averages
104.00
High
130.00
Current: 89.050
Low
65.00
Averages
104.00
High
130.00
JPMorgan
NULL
to
Overweight
maintain
$65 -> $105
2026-01-22
Reason
JPMorgan
Price Target
$65 -> $105
AI Analysis
2026-01-22
maintain
NULL
to
Overweight
Reason
JPMorgan raised the firm's price target on Structure Therapeutics to $105 from $65 and keeps an Overweight rating on the shares. The firm sees the upcoming data of the company's oral small molecule amylin, ACCG-2671, in the second half of 2026 adding " another leg to the story." Structure may have a "differentiated offering" in addition to aleniglipron, which is on track to be the second oral small molecule GLP-1 to market, the analyst tells investors in a research note.
Goldman Sachs
NULL
to
Buy
upgrade
$102
2026-01-19
Reason
Goldman Sachs
Price Target
$102
2026-01-19
upgrade
NULL
to
Buy
Reason
Goldman Sachs moved Structure Therapeutics (GPCR) to Buy rating and $102 price target from Early Stage Biotech. The company's oral small molecule GLP-1 aleniglipron has shown to be competitive against Eli Lilly's (LLY) orforglipron, the analyst tells investors in a research note. The firm views Structure's Phase 2 data as "de-risking" and sees scarcity value for the shares. Structure has a an oral small molecule that could be second to market only behind Lilly's orforglipron, contends Goldman.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GPCR
Unlock Now
H.C. Wainwright
Ananda Ghosh
Buy
upgrade
$60 -> $90
2025-12-19
Reason
H.C. Wainwright
Ananda Ghosh
Price Target
$60 -> $90
2025-12-19
upgrade
Buy
Reason
H.C. Wainwright analyst Ananda Ghosh raised the firm's price target on Structure Therapeutics to $90 from $60 and keeps a Buy rating on the shares. The firm says its key opinion leader feedback validates the company's titration strategy. With oral GLP-1s set to become "Tier 1 therapies" driven by payer economics, Structure's current valuation offers a "massive arbitrage opportunity relative to recent deal metrics with a strong M&A potential," the analyst tells investors in a research note. H.C. Wainwright views the company's recent Phase 2 data as encouraging.
Citi
Samantha Semenkow
Buy
maintain
$60 -> $100
2025-12-09
Reason
Citi
Samantha Semenkow
Price Target
$60 -> $100
2025-12-09
maintain
Buy
Reason
Citi analyst Samantha Semenkow raised the firm's price target on Structure Therapeutics to $100 from $60 and keeps a Buy rating on the shares. The positive Phase 2b data for aleniglipron gives Structure an attractive oral obesity asset, the analyst tells investors in a research note. The firm sees the drug getting "significant interest from strategics" looking to enter the oral obesity market. Citi believes aleniglipron showed "potential best-in-class" weight loss with competitive tolerability.
About GPCR
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
